During the meeting, Cartesian stockholders approved the issuance of shares of common stock upon conversion of Cartesian’s Series A Non-Voting Convertible Preferred Stock.

GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, ...